Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 59

Results For "Dash"

2634 News Found

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study
Biopharma | April 05, 2026

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred


BASF Pharma Solutions announces up to 20% price hike on excipients and APIs
News | April 04, 2026

BASF Pharma Solutions announces up to 20% price hike on excipients and APIs

The company said the increase—up to 20%—takes effect immediately, or as current contracts allow


Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib
Drug Approval | April 04, 2026

Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib

ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA


Abbott launches nationwide Vitamin C awareness campaign
Healthcare | April 04, 2026

Abbott launches nationwide Vitamin C awareness campaign

The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day


PHARMEXCIL Chintan Shivir in Hyderabad charts roadmap to scale India’s pharma exports
News | April 04, 2026

PHARMEXCIL Chintan Shivir in Hyderabad charts roadmap to scale India’s pharma exports

Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26


ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses
News | April 03, 2026

ZEISS India strengthens portfolio with the launch of ZEISS ClearMind lenses

Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology


Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
Biopharma | April 03, 2026

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning


Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra
Hospitals | April 03, 2026

Sahyadri Hospital brings first non-surgical treatment for severe knee pain to Maharashtra

Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure


Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer
News | April 03, 2026

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe


Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
Clinical Trials | April 03, 2026

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year